Search the Epitope Variant and Escape Mutation Database

Help

Found 1 matching record:

Displaying record number 55763

HXB2 Location Gag(77-85) Gag Epitope Map
View variants at this location

SLYNTVATL

`SLfNTVATL`		susceptible form
`SLYNlVATL`		susceptible form
`SLfNlVATL`		susceptible form
`SiYNlVATL`		susceptible form

Epitope Name SL9

Species (MHC/HLA) human, transgenic mouse(A2)

Variant Details

Showing all: 4 variant(s).

Variant ID.	`76`
Epitope Seq.	`SLYNTVATL`
Variant Seq.	`SLfNTVATL`
Mutations	Y/F
Epitope Location	Y3F
HXB2 Location	Y79F
Mutation Type	SF: susceptible form
Method	CD8 T-cell Elispot - IFNy, Chromium-release assay
Note	To identify immunogenically optimized epitopes for use in vaccines, mutants of SL9 were tested in transgenic mice. SLYNTVATL and most common mutant, SLfNTVATL, were weakly immunogenic or cross-reactive. 3 mutants, SLYNlVATL, SLfNlVATL and SiYNlVATL were highly immunogenic. Peptide SiYNlVATL with the additional L2I change allowed great cross-reactivity to the consensus.

Variant ID.	`77`
Epitope Seq.	`SLYNTVATL`
Variant Seq.	`SLYNlVATL`
Mutations	T/L
Epitope Location	T5L
HXB2 Location	T81L
Mutation Type	SF: susceptible form
Method	CD8 T-cell Elispot - IFNy, Chromium-release assay
Note	To identify immunogenically optimized epitopes for use in vaccines, mutants of SL9 were tested in transgenic mice. SLYNTVATL and most common mutant, SLfNTVATL, were weakly immunogenic or cross-reactive. 3 mutants, SLYNlVATL, SLfNlVATL and SiYNlVATL were highly immunogenic. Peptide SiYNlVATL with the additional L2I change allowed great cross-reactivity to the consensus.

Variant ID.	`78`
Epitope Seq.	`SLYNTVATL`
Variant Seq.	`SLfNlVATL`
Mutations	Y/F T/L
Epitope Location	Y3F T5L
HXB2 Location	Y79F T81L
Mutation Type	SF: susceptible form
Method	CD8 T-cell Elispot - IFNy, Chromium-release assay
Note	To identify immunogenically optimized epitopes for use in vaccines, mutants of SL9 were tested in transgenic mice. SLYNTVATL and most common mutant, SLfNTVATL, were weakly immunogenic or cross-reactive. 3 mutants, SLYNlVATL, SLfNlVATL and SiYNlVATL were highly immunogenic. Peptide SiYNlVATL with the additional L2I change allowed great cross-reactivity to the consensus.

Variant ID.	`79`
Epitope Seq.	`SLYNTVATL`
Variant Seq.	`SiYNlVATL`
Mutations	L/I T/L
Epitope Location	L2I T5L
HXB2 Location	L78I T81L
Mutation Type	SF: susceptible form
Method	CD8 T-cell Elispot - IFNy, Chromium-release assay
Note	To identify immunogenically optimized epitopes for use in vaccines, mutants of SL9 were tested in transgenic mice. SLYNTVATL and most common mutant, SLfNTVATL, were weakly immunogenic or cross-reactive. 3 mutants, SLYNlVATL, SLfNlVATL and SiYNlVATL were highly immunogenic. Peptide SiYNlVATL with the additional L2I change allowed great cross-reactivity to the consensus.

References

Blondelle2008 Sylvie E. Blondelle, Rosa Moya-Castro, Keiko Osawa, Kim Schroder, and Darcy B. Wilson. Immunogenically Optimized Peptides Derived from Natural Mutants of HIV CTL Epitopes and Peptide Combinatorial Libraries. Biopolymers, 90(5):683-694, 2008. PubMed ID: 18481808. Show all entries for this paper.